AF-45 inhibits IRAK4 and IRAK1, with IC50s of 128 nM and 1765 nM. AF-45 inhibits the release of IL-6 and TNF-alpha in macrophages, with IC50s of 0.53-1.54 µM and 0.6-2.75 µM. AF-45 is also an inhibitor for NF-kappaB/MAPK signaling pathway. AF-45 exhibits anti-inflammatory activities against DSS-induced ulcerative colitis and Lipopolysaccharide (HY-D1056)-induced acute lung injury in mouse model. AF-45 exhibits good pharmacokinetic characteristics in rat models[1].
Molekulargewicht:
379.45
Formel:
C22H25N3O3
Target-Kategorie:
IRAK,NF-kappaB,p38 MAPK,TNF Receptor
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
